SMS Pharma Q1FY27: Revenue up 6% YoY to ₹207 Cr, PAT up 8% to ₹20 Cr
SMS Pharmaceuticals Limited's Q1FY27 revenue grew 6% YoY to ₹207 crore, with PAT up 8% to ₹20 crore. The company completed 4 DMF/CEP filings and is on track for its FY27 target. A ₹280 crore capex program is underway. The board approved a ₹50 crore loan infusion into subsidiary SMS Peptides.
The results show steady growth and strategic investments, which are positive indicators for the company's future performance. The increase in revenue and PAT, coupled with ongoing capex and R&D expansion, suggests a positive outlook.
The company reported positive year-on-year growth in revenue and profit, maintained healthy margins, and is progressing on its strategic initiatives including capex and subsidiary investment, along with regulatory filings.
SMS Pharmaceuticals Limited has announced its financial results for the quarter ended June 30, 2026 (Q1FY27). The company reported a 6% year-on-year increase in revenue from operations, reaching ₹207 crore, driven by diversified growth across high-value Active Pharmaceutical Ingredients (APIs).
Gross margins were maintained above 45%, indicating structural improvements in unit economics. The EBITDA margin stood steady at approximately 20%, with Profit After Tax (PAT) seeing an 8% year-on-year rise to ₹20 crore. Earnings Per Share (EPS) was ₹2.23.
The company completed 4 Drug Master File (DMF)/Certificate of Suitability (CEP) filings during the quarter and is on track to meet its full-year target of 10 such filings for FY27. A capital expenditure (capex) program of ₹280 crore is progressing as planned and is expected to be completed by FY27.
In a strategic move to support its subsidiary, SMS Peptides Private Limited, the board has approved an infusion of up to ₹50 crore as a loan. This follows an ₹8 crore investment made in FY26 to establish a dedicated peptide R&D facility. The R&D team has been expanded to 200 members to bolster the development pipeline for niche and high-value APIs and peptides.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.